Filter Results:
(10)
Show Results For
- All HBS Web
(24)
- News (3)
- Research (10)
- Events (1)
- Multimedia (1)
- Faculty Publications (12)
Show Results For
- All HBS Web
(24)
- News (3)
- Research (10)
- Events (1)
- Multimedia (1)
- Faculty Publications (12)
Page 1 of 10
Results
Sort by
- August 2019
- Case
Synthetic Biology Investment Opportunity
By: Peter Barrett, Karim R. Lakhani, Julia Kelley and Kerry Herman
Using an overview of the emerging technology of Synthetic Biology, this case provides the basis for discussion on what questions one would ask in evaluating a potential investment in the field. View Details
Barrett, Peter, Karim R. Lakhani, Julia Kelley, and Kerry Herman. "Synthetic Biology Investment Opportunity." Harvard Business School Case 620-015, August 2019.
- Oct 2008
- Conference Presentation
The Rumpelstiltskin Effect: Synthetic Biology and International Trade
By: Gautam Mukunda and Rachel Wellhausen
- 15 Jun 2011 - 17 Jun 2011
- Conference Presentation
A multi-disciplinary process for assessing synthetic biology applications
By: Gautam Mukunda, Allen Lin and Kenneth Oye
Keywords: Science
- December 2009
- Article
Aspects of the Political Economy of Development and Synthetic Biology
By: Rachel Wellhausen and Gautam Mukunda
Wellhausen, Rachel, and Gautam Mukunda. "Aspects of the Political Economy of Development and Synthetic Biology." Systems and Synthetic Biology 3, nos. 1-4 (December 2009): 115–123.
- October 2022 (Revised May 2023)
- Case
Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues
Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But... View Details
Keywords: Fraud Allegations; Revenue; Reports; Accounting Audits; Innovation and Management; Investment; Biotechnology Industry; Boston
Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022. (Revised May 2023.)
- February 2010
- Case
Amyris Biotechnologies: Commercializing Biofuel
By: Gary P. Pisano and Alison Berkley Wagonfeld
In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details
Keywords: Renewable Energy; Chemicals; Risk Management; Product Marketing; Product Development; Production; Environmental Sustainability; Commercialization; Biotechnology Industry; Brazil
Pisano, Gary P., and Alison Berkley Wagonfeld. "Amyris Biotechnologies: Commercializing Biofuel." Harvard Business School Case 610-031, February 2010.
- October 2019 (Revised November 2019)
- Case
C16 Biosciences: Lab-Grown Palm Oil
By: Jeffrey J. Bussgang and Olivia Hull
Synthetic biology start-up C16 Biosciences wants to solve a big problem: replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. CEO Shara Ticku has ambitious plans to supply her lab-grown palm oil to food manufacturers,... View Details
Keywords: Science-Based Business; Environmental Sustainability; Social Entrepreneurship; Product Development; Product Positioning; Venture Capital; Strategy; Decision Making; Food and Beverage Industry; Consumer Products Industry
Bussgang, Jeffrey J., and Olivia Hull. "C16 Biosciences: Lab-Grown Palm Oil." Harvard Business School Case 820-008, October 2019. (Revised November 2019.)
- 11 May 2010
- First Look
First Look: May 11
Amyris Biotechnologies: Commercializing Biofuel Gary P. Pisano and Alison Berkley WagonfeldHarvard Business School Case 610-031 In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic View Details
Keywords: Martha Lagace